Novartis announced that The New England Journal of Medicine (NEJM) published data for PKC 412 (midostaurin) demonstrating an overall response...
Clinically relevant features in patients with systemic mastocytosis (SM) include the cosmetic burden of lesional skin, mediator-related symptoms, and organ damage resulting from mast cell (MC) infiltration in advanced forms of SM.
Novartis has announced that the FDA granted Priority Review to the PKC 412 (midostaurin) new drug application (NDA) for the...
Novartis announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion...
This study will investigate if the drug midostaurin taken orally twice daily is effective and safe in treating patients with aggressive systemic mastocytosis or mast cell leukemia with or without an additional hematological neoplasm.
The development of FLT3-targeted inhibitors represents an important paradigm shift in the management of patients with highly aggressive fms-like tyrosine kinase 3-mutated (FLT3-mut) acute myeloid leukemia (AML).
Novartis has announced positive results from the global Phase III RATIFY (CALGB 10603) clinical trial. In the study, adult patients...
Novartis has announced that the European Commission approved Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers. Rydapt is approved...